Treating H. pylori shorter than one week - a real future perspective?

Summary

Background: We assessed the current impact of H. pylori eradication therapies with a short (4-6 days) and very short (≤ 3 days) duration of antibiotic treatment because of possible advantages in terms of costs and side effects over standard one-week triple therapy

Methods: The literature was reviewed and 35 studies analyzed, leading to a total of 51 treatment regimens with 2177 patients.

Results: Cumulative per-protocol H. pylori eradication rates were 61.3 %, 75.2 %, and 79.4 % for dual, triple and quadruple therapies, respectively. Dual therapy was inferior to triple and quadruple regimens (p < 0.001), while the difference between triple and quadruple therapy did not reach statistical significance. Subgroup analysis of all triple therapies containing macrolides and imidazoles resulted in a success rate of 84.1 % (vs. 62.1 % for other triple therapies, p < 0.0001). Decreasing the treatment duration to 3 days or less resulted in a loss of efficacy for both bismuth-based quadruple therapy with tetracycline and imidazoles (90.3 % vs. 65 %, p < 0.0001) and for triple therapy with macrolides and amoxicillin (70.3 % vs. 31.2 %, p < 0.0001). This does not hold true for triple therapy containing imidazoles and macrolides (84.5 % vs. 83.6 %, not significant). Regardless of the duration of therapy quadruple regimes with macrolides/imidazoles/amoxicillin achieved an eradication rate of 91.9 %.

Conclusions: Preliminary data suggest that the short-term combination of proton pump inhibitors with 2 antibiotics (macrolides and imidazoles) with/without amoxicillin may be as effective as standard one week triple therapies, even for treatment durations of 3 days or less. The combination of proton pump inhibitors with bismuth, tetracyclin and imidazoles appears to be equally effective, if given for at least 4 days.

Kurzzeittherapie der H.-pylori-Infektion - eine Erfolg versprechende Perspektive?

Einleitung: Die vorliegende Literaturübersicht versucht den Stellenwert einer Kurzzeittherapie (4-6 Tage) und Ultrakurzzeittherapie (≤ 3 Tage) zur Behandlung der H.-pylori-Infektion zu beschreiben, da Vorteile im Hinblick auf Kosteneffizienz und Nebenwirkungen denkbar sind.

Methoden: Es erfolgte eine Literaturanalyse von 35 Studien, welche 51 Therapieregime mit insgesamt 2177 behandelten Patienten umfassten.

Ergebnisse: Kumulative per Protokoll H.-pylori-Eradikations­raten betrugen 61,3 %, 75,2 % und 79,4 % für eine Zweifach-, Dreifach- oder Vierfachtherapiekombination. Die Dualtherapie war allen anderen Kombinationen unterlegen (p < 0.001), wohingegen die Drei- und Vierfachkombination sich nicht signifikant voneinander unterschieden. Eine Subgruppenanalyse ergab einen Vorteil für alle Triple-Regime welche Makrolide und Imidazole enthielten (84,1 % vs. 62,1 % für alle anderen Tripletherapien, p < 0,0001). Die Verkürzung der Therapiedauer auf 3 Tage und weniger war von Nachteil für die wismuthaltige Vierfachtherapie mit Tetrazyklin und Imidazolen sowie für die Dreifachtherapie mit Makroliden und Amoxicillin (90.3 % vs. 65 % und 70,3 % vs. 31,2 %, jeweils p < 0,0001), aber statistisch bestand kein signifikanter Unterschied für eine Dreifachtherapie mit Makroliden und Imidazolen (84,5 % vs. 83,6 %). Die ­Vierfachtherapie mit Makroliden, Imidazolen und Amoxicillin erzielte unabhängig von der Therapiedauer 91,9 %.

Schlussfolgerung: Vorläufige Daten legen den Schluss nahe, dass eine Kurzzeitherapie mit Protonenpumpenhemmern und 2 Antibiotika (Makrolide und Imidazole) ± Amoxicillin ähnlich wirksam wie eine einwöchige Dreifachstandardtherapie ist. Gleiches trifft zu für eine Therapie mit Protonenpumpenhemmern, Wismut, Tetrazyklin und Imidazolen, wenn über min­destens 4 Tage behandelt wird.

Key words

Helicobacter Pylori - Eradication Therapy - Short Term - Review

Schlüsselwörter

Helicobacter Pylori - Eradikation - Kurzzeittherapie - Übersicht

References

• 1 Treiber G, Lambert J R. The impact of Helicobacter pylori eradication on peptic ulcer healing.  Am J Gastroenterol. 1998;  93 1080-4
• 2 Penston G. Clinical aspects of helicobacter pylori eradication therapy in peptic ulcer disease.  Aliment Phramacol Ther. 1996;  10 469-86
• 3 Huang J Q, Sridhar S, Chen Y  et al. Meta-analysis of the relationship between helicobacter pylori seropositivity and gastric cancer.  Gastroenterology. 1998;  114 1169-79
• 4 Watanabe T, Tada M, Nagai H. Helicobacter pylori infection induces gastric cancer in mongolian gerbils.  Gastroenterology. 1998;  115 642-8
• 5 Penston J G, McColl K EL. Eradication on Helicobacter pylori: An objective assessment of current therapies.  Br J Clin Pharmacol. 1997;  43 223-43
• 6 Van der Hulst R WM, Keller J J, Rauws E AJ. Treatment of helicobacter pylori infection: A review of the world literature.  Helicobacter. 1996;  1 6-19
• 7 Treiber G. The influence of drug dosage on Helicobacter pylori eradication. A cost- effectiveness analysis.  Am J Gastroenterol. 1996;  91 246-57
• 8 Malfertheiner P, Megraud F, O’Morain C. Current european concepts in the management of Helicobacter pylori infection - the Maastricht Consensus report.  Gut. 1997;  9 1-2
• 9 Pipkin G A, Williamson R, Wood J R. Review article: One-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori.  Aliment Pharmacol Ther. 1998;  12 823-37
• 10 Peitz U, Menegatti M, Vaira D. et al . The European meeting on helicobacter pylori: Therapeutic news from Lisbon.  Gut. 1998;  43 (Suppl. 1) S66-9
• 11 Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori.  Gastroenterology. 1998;  115 1278-82
• 12 DeBoer W A, VanEtten R J, Schade R W. One-day intensified lansoprazole-quadruple therapy for cure of helicobacter pylori infection.  Aliment Pharmacol Ther. 1997;  11 109-12
• 13 DeBoer W A, Van Etten R J, Coremans A. Two-day weekend lasoprazole-quadruple therapy for helicobacter pylori infection.  Aliment Pharmacol Ther. 1998;  12 77-81
• 14 Kung N NS, Sung J JY, Yuen N WF. et al . Anti-helicobacter pylori treatment in bleeding ulcers: Randomized controlled trial comparing 2-day vs. 7-Day bismuth quadruple therapy.  Am J Gastroenterol. 1997;  92 438-42
• 15 DeBoer W A, Driessen W MM, Tytgat G NJ. Only four days of quadruple therapy can effectively cure Helicobacter pylori infection.  Aliment Phramacol Ther. 1995;  9 633-8
• 16 DeBoer W A, vanEtten R JXM, Schade R WB. 4-day lansoprazole quadruple therapy: A highly effective cure for Helicobacter pylori infection.  Am J Gastroenterol. 1996;  91 1778-82
• 17 Treiber G, Ammon S, Schneider E. Amoxicillin/ Metronidazole/ Omeprazole/ Clarithromycin: A new, short quadruple therapy for helicobacter pylori eradication.  Helicobacter. 1998;  3 54-8
• 18 Caselli M, Ruina M, Gallerani L. et al . Azithromycin and increasing doses of omeprazole for the eradication of helicobacter pylori.  Gut. 1996;  39 (Suppl. 2) A31
• 19 Hermida C, Moreno J A, Carpintero P. et al . Triple therapy for helicobacter pylori eradication in patients with chronic gastritis. Twelve days better than six.  Gut. 1996;  39 (Suppl. 2) A33
• 20 Takats A, Racz I, Boga B. Efficacy of a „one-day-triple-therapy” with potentialisation of omeprazole for eradication of helicobacter pylori.  Am J Gastroenterol. 1994;  89 1399 (A455)
• 21 Seelis R, Dohmen W. 6-Day eradication treatment of helicobacter pylori infection in a non-hospital practice.  Dtsch med Wschr. 1998;  123 103-8
• 22 Dominguez-Martin A, Dominguez-Munoz A, Munoz S. et al . Efficacy of six days triple therapy with pantoprazole plus clarithromycin and amoxicillin versus omeprazole plus clarithromycin and amoxicillin for helicobacter pylori eradication.  Gastroenterology. 1998;  114 A 107
• 23 Seelis R, Dohmen W. Only once a day for six days: Compliance effective triple-therapy against helicobacter pylori disease.  Gastroenterology. 1998;  114 (suppl) A 281
• 24 Pieramico O, Zanetti M V, Innerhofer M. Three-days and seven-days triple therapy with clarithromycin or azithromycin for cure of helicobacter pylori infection.  Gastroenterology. 1998;  114 A 258
• 25 Grimley C E, Penny A, O’Sullivan M. et al . Comparison of 2 three-day helicobacter pylori eradication regimens with a standard one week regimen.  Aliment Pharmacol Ther. 1999;  13 869-73
• 26 Caselli M, Ruina M, Sartori S. et al . Ultra short-term triple therapy with azithromycin, tinidazole and pantoprazole appears highly effective for helicobacter pylori eradication.  Gastroenterology. 1998;  114 A 85
• 27 Treiber G, Wittig J, Ammon S. et al . New short-term quadruple therapies for eradication of helicobacter pylori (H. pylori): MACLOR study.  Gastroenterology. 1998;  114 A312
• 28 Tucci A, Poli L, Paparo G F. Weekend therapy for the treatment of Helicobacter pylori infection.  Am J Gastroenterol. 1998;  93 737-42
• 29 Kung N N, Sung J J, Yuen N W. Anti-Helicobacter pylori treatment in bleeding ulcers: Randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.  Am J Gastroenterol. 1997;  92 438-41
• 30 Trevisani L, Sartori S, Caselli M. A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection.  Am J Gastroenterol. 1998;  93 390-3
• 31 DeBoer W A, van Etten R J, Schneeberger P M. Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection.  Neth J Med. 1998;  52 10-5
• 32 Tucci A, Corinaldesi R, Stanghellini V. One-day therapy for treatment of Helicobacter pylori infection.  Dig Dis Sci. 1993;  38 1670-3
• 33 Takats A, Gero G, Szentmihalyi A . et al .The difference of efficacy in azithromycin containing short time dual therapy versus one-day quadruple therapy for the eradication of helicobacter pylori. Abstract book of the second annual winter. H. pylori workshop of the foundation for gastrointestinal microbial pathogens Phoenix, AZ, U.S.A; 1998 27-28 A 29. 
• 34 Kadus W, Rehmann I. Shortened triple regimen for eradication of H. pylori: Very first results of a prospective therapy surveillance. Abstract book of the second annual winter. H. pylori workshop of the foundation for gastrointestinal microbial pathogens Phoenix, AZ, U.S.A; 1998 27-28 A 23. 
• 35 O’Connor H J, McLoughlin R, Kelly S. et al . Lansoprazole triple therapy for helicobacter pylori - is 5 days enough?.  Aliment Pharmacol Ther. 1998;  12 273-6
• 36 Neville P M, Everett S, Langworthy H. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen.  Aliment Pharmacol Ther. 1999;  13 497-501
• 37 DeBoer S Y, Siem T H. Four-day quadruple therapy as a routine treatment for helicobacter pylori infection.  Aliment Pharmacol Ther. 1997;  11 1119-21
• 38 Katicic M, Presecki V, Prskalo M. et al . A new dual and triple therapies in eradicating helicobacter pylori in peptic ulcer patients.  Gut. 1998;  43 (Suppl. 2) A 86
• 39 Comet R, Tito L, Calvet X. et al . Twice a day, four-day, quadruple therapy for treatment of helicobacter pylori infection: A pilot study.  Gut. 1998;  43 (Suppl. 2) A 90
• 40 Cammarota G, Papa A, Cianci R. 3-Day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure helicobacter pylori infection.  Eur J Gastroenterol Hepatol. 1999;  11 247-50
• 41 Caselli M, Trevisani L, Tursi A. Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of helicobacter pylori.  Eur J Gastroenterol Hepatol. 1997;  9 45-8
• 42 Vcev A, Vceva A, Ivandic A. Omeprazole and azithromycin with and without metronidazole in the eradication of Helicobacter pylori in duodenal ulcer disease.  Lijec Vjesn. 1997;  119 210-3
• 43 Pilotto A, Di Mario F, Franceschi M. Cure of Helicobacter pylori infection in the elderly: Effects of eradication on gastritis and serological markers.  Aliment Pharmacol Ther. 1996;  10 1021-7
• 44 Gisbert J P, Boixe D, Bermejo F. et al . Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient?.  Rev Clin Esp. 1998;  198 655-9
• 45 Savarino V, Zentilin P, Bisso G. Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection.  Aliment Pharmacol Ther. 1999;  13 43-7
• 46 Wermeille J, Cunningham M, Armenian B. Failure of a 1-day high-dose quadruple therapy for cure of Helicobacter pylori infection.  Aliment Pharmacol Ther. 1999;  13 173-7
• 47 Graham D Y, deBoer W A, Tytgat G. Choosing the best anti-Helicobacter pylori therapy: Effect of antimicrobial resistance.  Am J Gastroenterol. 1996;  91 1072-6
• 48 Peitz U, Sulliga M, Nusch A. et al . Randomised study on the impact of resistance on second-line treatment after failed metronidazole-clarithromycin containing triple therapy.  Gut. 1998;  43 (Suppl. 2) A82
• 49 Peitz U, Nusch A, Tillenburg B. et al . Impact of treatment duration and metronidazole resistance on H.pylori cure with omeprazole, metronidazole, and clarithromycin.  Gastroenterology. 1997;  112 (Suppl.) A255
• 50 Laine L, Suchower L, Frantz J. Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy.  Aliment Pharmacol Ther. 1998;  9 887-92
• 51 Svensson M, Sörberg M, Nilsson M. et al . Do combinations with nitroimidazoles or amoxicillin prevent development of clarithromycin resistance in helicobacter pylori?.  Gut. 1999;  43 (Suppl.) abstract
• 52 Okada M, Nishimura H, Kawashima M. A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome.  Aliment Pharmacol Ther. 1999;  13 769-74
• 53 Graham D Y. Antibiotic resistance in Helicobacter pylori: Implications for therapy.  Gastroenterology. 1998;  115 1272-7
• 54 van Doorn LJ, Schneeberger PM, Nouhan N. et al . Importance of Helicobacter pylori cag A and vac A status for the efficacy of antibiotic treatment.  Gut. 2000;  46 321-6
• 55 Marais A, Monteiro L, Lamonliatte H. et al . Cag negative status of Helicobactor pylori is a risk factor for failure of PPJ based triple therapies in non-ulcer dyspepsia.  Gastroenterology. 1998;  114 (Suppl.) abstract

Address for correspondence